View More Recent Stories

Jan 6, 2025 09:03AM ImmunityBio (IBRX) Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective
Jan 6, 2025 09:00AM ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective
Nov 21, 2024 10:01AM ImmunityBio (IBRX) and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment
Nov 21, 2024 10:00AM ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment
Nov 19, 2024 08:00AM ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Rang
Nov 12, 2024 07:15AM ImmunityBio Reports Third-Quarter 2024 Financial Results
Oct 24, 2024 09:00AM First Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma
Oct 21, 2024 09:00AM ImmunityBio to Participate in the Jefferies London Healthcare Conference
Jul 27, 2023 11:33AM GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IBRX
Jul 21, 2023 10:25PM GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IBRX
Oct 26, 2022 09:31PM Faraday Future Announces Chief Accounting Officer and Interim Chief Financial Officer, and Funding Progress
Jun 23, 2021 04:05PM Motus GI Appoints Experienced Financial Biotech Executive, Sonja Nelson, to its Board of Directors and as Chair of Audit Committee
View More Recent Stories